Low Doses of Celecoxib Attenuate Gut Barrier Failure During Experimental Peritonitis

Scott S. Short1,2, Jin Wang1, Shannon L. Castle1,2, G. Esteban Fernandez3, Nancy Smiley1, Michael Zobel1, Elizabeth M. Pontarelli1,2, Stephanie C. Papillon1,2, Anatoly V. Grishin1,2, and Henri R. Ford1,2

1Division of Pediatric Surgery, Children’s Hospital Los Angeles, Los Angeles, CA
2Department of Surgery, University of Southern California, Los Angeles, CA
3Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA

Abstract

The intestinal barrier becomes compromised during systemic inflammation, leading to entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E2 (PGE2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction-associated proteins JAM-A and ZO-1. Luminal instillation of PGE2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5–1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising tight junctions. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.

Keywords

peritonitis; gut barrier failure; gut origin sepsis; cyclooxygenase-2; prostaglandin E2; Celecoxib
14), and acute illness (15–17). Furthermore, inflammatory gut barrier failure is a part of multiple organ dysfunction syndrome (3, 18). Finding ways to prevent or ameliorate the inflammatory gut barrier failure is therefore an important area of ongoing basic and clinical research.

How inflammation leads to gut barrier failure is not well understood. Barrier function of the intestinal epithelium critically depends on tight junctions (TJ), the structures that seal enterocyte borders. TJ consist of integral proteins (occludin and claudins) that form a tight seal of the apical intercellular space, and associated cytosolic proteins (zonula occludens-1, ZO-1; and junction-associated molecule-A, JAM-A) that connect the TJ to intracellular actinomyosin complexes (19). TJ undergo continuous remodeling during epithelial renewal, as evidenced by internalization and re-deposition of the junctional proteins (20). Under conditions causing barrier breakdown, a dynamic balance between these two opposing processes is shifted towards the internalization. A variety of inflammatory factors including IL-1β (21, 22), IL-4 (23), IL-6 (24), TNF (25–31), IFN-γ (32–35), High Mobility Group B (36, 37), nitric oxide (38–41), and inflammatory prostanooids (42–45) each can increase gut barrier permeability in vitro and/or in vivo, indicating the multifactorial character of gut barrier failure.

Roles of prostanooids in gut barrier function under normal and pathologic conditions are fairly complex. Prostanoids are oxygenated fatty acids derived from membrane arachidonate via the rate-limiting oxygenation and peroxidation reactions catalyzed by COX-1 and COX-2 cyclooxygenases. Since COX-1 COX-2 double KO mice die early postpartum, the cyclooxygenase activity is essential (46). The main prostanoid in the intestine is PGE2 (47). Low levels of prostanooids produced under normal conditions by constitutive expression of COX-1 and basal expression of COX-2 regulate ion transport, intestinal secretion, cell migration, blood vessel and smooth muscle tone; they suppress production of inflammatory cytokines and are required for barrier maintenance and intestinal homeostasis (48). High levels of prostanoids resulting from transcriptional induction of COX-2 during inflammation orchestrate the innate and adaptive immune responses (49). They promote production of nitric oxide and vasodilation (48), angiogenesis (50), hyperalgesia (51, 52), smooth muscle contraction (53), and enterocyte proliferation (54). Increased expression of COX-2 is one of the key factors in the pathogenesis of gut barrier failure during inflammatory bowel disease (55–57) and necrotizing enterocolitis (58). Apparently, responses to low and high concentrations of prostanoids are quite different.

If high levels of prostanoids damage the gut barrier, inhibition of prostanoid production may seem an obvious treatment strategy. Under the assumption that protective effects of low-level prostanoids are provided by COX-1, COX-2 appears the preferred target. Indeed, under certain scenarios COX-2 inhibitors have been reported to protect the barrier (59–62). However, other studies have found that COX-2 inhibitors do not protect, but rather aggravate the barrier damage in experimental colitis and necrotizing enterocolitis (63–66). Moreover, specific COX-2 inhibitors have been found to exhibit gut toxicity, albeit not to the extent of nonspecific COX inhibitors (67, 68). This is not surprising, since both COX-1 and COX-2 are necessary for barrier protection under adverse conditions (69, 70), with
COX-2 actually being more important than COX-1 in this role (71). Thus, it might seem that COX-2 inhibitors are not useful as a therapy for inflammatory gut barrier failure.

We hypothesized that low doses of a specific inhibitor that attenuate, rather than completely inhibit COX-2, would protect the barrier during inflammation by dampening the detrimental effects of high levels, yet preserving the beneficial effects of low levels of COX-2 activity. This hypothesis was tested using experimental peritonitis models in mice. LPS injection or cecal ligation and puncture (CLP) increased expression of COX-2 and levels of PGE$_2$ in the ileal mucosa and caused barrier derangement. The barrier was also compromised by luminal instillation of PGE$_2$. Low (0.5 mg/kg), but not high (5 mg/kg) dose of the COX-2-specific inhibitor Celecoxib significantly protected the barrier during peritonitis. Low doses of COX-2 inhibitors may thus find use as adjunct barrier protection therapy in critically ill patients.

**Materials and Methods**

**Reagents and Antibodies**

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Commensal *E. coli* strain 35354T was obtained from ATCC (Manassas, VA) and transformed with the pUC18 plasmid to confer ampicillin resistance. Antibodies were from the following suppliers: COX-2 (cat. 16016), EP1 (cat. 101740), EP2 (cat. 101750), EP3 (cat. 101760) and EP4 (cat. 101755) receptors, Cayman Chemical (Ann Arbor, MI); iNOS (cat. 610432), BD Transduction Laboratories (San Jose, CA); ZO-1 (cat. B2129), Lifespan Biosciences (Seattle, WA), JAM-A (cat. 361700), Invitrogen (Carlsbad, CA); β-actin (cat. A1978), Sigma-Aldrich. All primary antibodies were rabbit polyclonal except iNOS and β-actin, which were mouse monoclonal. Secondary antibodies for immunofluorescence (FITC or Texas Red-conjugated donkey anti-rabbit) or Western blot (horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse) were from Jackson ImmunoResearch (West Grove, PA). PGE$_2$ (cat. 514531) and IL-6 (cat. 583371) ELISA kits were from Cayman Chemical.

**Animals**

All procedures were designed in adherence to the National Institutes of Health Guidelines on Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Children’s Hospital Los Angeles. C57Bl/6J mice were either bred in-house or purchased from Jackson Labs (Sacramento, CA). COX-2-deficient mice were purchased from Jackson Labs and bred heterozygous. *cox-2$^{-/-}$* mice were derived from crosses involving *cox-2$^{+/-}$* parents. Mice were genotyped as recommended by the supplier. Healthy animals of both sexes, 8–12 wk old and weighting 18–26 g were used in experiments. We did not observe significant differences between sexes or between younger and older animals in this study. Survival surgeries were performed under isoflurane anesthesia and followed by buprenorphine s.c. to minimize post-operative pain. Experimental peritonitis was induced by i.p. injection of 40 mg/kg LPS from *E. coli* 0127:B8, or by CLP (72). In the latter procedure, the cecum was externalized through abdominal incision, tied with a silk suture, and punctured two times with 21-gauge needle. The cecum was returned to the peritoneal cavity.
and incision closed with staples. Sham operation was performed similarly, but punctures were omitted.

**Assessment of barrier function**

30 min prior to the induction of peritonitis, mice were orally gavaged with 200 μl of test mixture, normal saline (NS) containing 22 mg/ml FITC-Dextran, MW=4 kDa, and 5×10⁸ cfu/ml ampicillin-resistant *E. coli* 35354T. 16 h post LPS injection or CLP, blood samples (~400 μl) were collected by cardiac puncture. Serum was prepared by centrifugation at 10,000xg for 10 min. Concentrations of FITC-dextran in serum were determined by fluorometry and interpolation to standard curve. Mesenteric lymph nodes, spleens, and livers were aseptically excised, weighted, ground in a Dounce homogenizer, and serially diluted. Titers of *E. coli* were determined by plating dilutions onto LB agar supplemented with 100 mg/L ampicillin.

**Effect of luminally-instilled PGE₂**

2 h before surgery, mice were gavaged with 200 μl of 22 mg/ml FITC-dextran in NS. Isoflurane-anesthetized animals were placed on a warm pad. A 3 cm loop of terminal ileum was externalized through abdominal incision and clamped. 200 μl of 50 μM PGE₂ in NS was injected into the lumen of the isolated loop through a 27-gauge needle. The externalized intestinal loop was covered with moist gauze to prevent drying. 25 min after PGE₂ treatment, blood was collected for measuring serum FITC-dextran.

**Immunoflorescence microscopy**

4 μm paraffin sections of terminal ileum were deparaffinized and re-hydrated by boiling in 10 mM sodium citrate. After blocking with 5% normal donkey serum, the sections were incubated with primary and secondary Cy3-conjugated antibodies as recommended by manufacturers. Slides were mounted with DAPI mounting medium. Images were acquired on an LSM 700 confocal system mounted on an AxioObserver Z1 microscope equipped with a 40×/1.3 Plan-NEOFLUAR oil-immersion lens and controlled by ZEN 2009 software (Carl Zeiss Microimaging, Thornwood, NY). Fluorescence excitation lasers and emission filters were 405 nm excitation with short-pass 490 nm emission for DAPI and 555 nm excitation with long-pass 560 nm emission for Cy3. The confocal pinhole was set to 1 Airy unit for Cy3. To increase the contiguous area that was imaged, the optical zoom factor was set to 0.5 and adjacent fields of view were tiled together with no overlap. For comparisons, sections were processed in parallel on the same slide, and images were acquired and adjusted identically.

**Western blots**

Mucosal scrapings from terminal ileum were extracted on ice with buffer (20 mM Tris pH 8.0, 100 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 0.5 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 1 mM benzamidine. Solubilized proteins (50 μg) were separated by SDS-PAGE. Gels were electroblotted onto nitrocellulose membranes, which were then blocked in PBS-Tween with 2% fish gelatin, incubated with primary antibody, washed, and incubated with horseradish peroxidase-conjugated secondary

*Lab Invest. Author manuscript; available in PMC 2014 June 01.*
antibody. After washing and soaking in luminol-peroxide reagent, membranes were exposed to X-ray film.

ELISA

30 mg (wet wt) of ileal mucosal scrapings were homogenized with 1 ml PBS supplemented with 0.5 mM PMSF in a Dounce homogenizer. The homogenate was cleared by centrifugation. ELISA was performed using PGE$_2$ and IL-6 kits as directed by their manufacturers.

Statistics

Quantitative data were compared using Wilcoxon’s test or Student’s t test of the statistical software package JMP (Cary, NC). A p-value of < 0.05 was considered significant.

Results

Peritonitis is associated with COX-2 induction and high levels of prostaglandin E$_2$ in ileal mucosa

To gain insight into the mechanisms of inflammatory gut barrier failure in vivo, we employed the two well-characterized mouse models of systemic inflammation/sepsis/peritonitis, i.p. injection of LPS and CLP. Each model has its advantages and disadvantages: the former is more controlled but less clinically relevant, whereas the opposite is true for the latter. We reasoned that using two different models would at least partially mitigate their disadvantages. The dose of LPS or the parameters of the CLP procedure (number of punctures and needle gauge) were adjusted to cause ~50% mortality in 36 h. Within hours after peritonitis-inducing treatments, mice developed outward signs of fever including lethargy, hunched posture, ruffled fur, and anorexia. By the time of sacrifice (16 h) over 96% of animals were alive.

Systemic inflammation is associated with high levels of prostanoids resulting from upregulation of COX-2. We hypothesized that high levels of COX-2-derived prostanoids, particularly PGE$_2$, might be directly responsible for the increased gut barrier permeability. Since prostanoids are metabolically labile and act locally (73), such a mechanism would imply induction of the COX-2 gene and increased concentrations of PGE$_2$ in the intestinal tissue. To test this, we assessed expression of the COX-2 protein and measured levels of PGE$_2$ in the mucosa of the small intestine during experimental peritonitis. Since PGE$_2$ is rapidly converted in vivo into inactive stable metabolites 13,14-dihydro-15-keto PGE$_2$ and 13,14-dihydro-15-keto PGA$_2$ (hereinafter PGE$_2$ metabolites), actually the levels of these metabolites were measured by the assay.

COX-2 protein levels in the ileal mucosa were markedly elevated following LPS injection or CLP compared to NS injection or sham operation, as judged by Western blots (Figure 1a). Consistent with high levels of COX-2, there was also a significant increase in production of PGE$_2$ in the mucosa (Figure 1b). Immunofluorescence microscopy revealed that the bulk of COX-2 was induced in the epithelium and in few cells within the lamina propria.
presumably lymphocytes (Figure 1c). Immunostaining for COX-2 was specific because no signal was detected in the intestinal sections from \textit{cox2}^{−/−} mice (Figure 1c, Neg).

Responses to \textit{PGE}_2 are mediated by the four \textit{PGE} receptors, EP1–4. In order to test whether the intestinal epithelium is capable of sensing \textit{PGE}_2, we performed immunofluorescence analysis of \textit{EP} receptor expression in small intestinal sections. For all four receptors, highest levels of expression were observed in the epithelium. For EP1, 2, and 4, the signal was strongest at the luminal interface and somewhat weaker within enterocyte bodies; EP3 was largely limited to crypt epithelium (Figure 1d). Intracellular \textit{EPs} are likely due to the ongoing receptor biogenesis and/or internalization. Immunostaining for \textit{EP} receptors was specific because no signal was detected if the primary antibody was substituted for normal serum (Figure 1d, Neg). We did not observe any consistent change in \textit{EP} receptor expression or localization associated with experimental peritonitis (unpublished results). Taken together, these data indicate that COX-2 is induced, and \textit{PGE}_2 levels increase in the mucosa during experimental peritonitis. Moreover, enterocytes possess the full complement of \textit{PGE} receptors to enable sensing of the inflammatory \textit{PGE}_2.

**Experimental peritonitis is associated with gut barrier derangement**

Morphology, passage of FITC-dextran from gut lumen to bloodstream, and bacterial translocation to lymphatic organs and liver were used to characterize the state of the gut barrier during peritonitis. The most prominent morphologic feature on the \textit{hematoxylin-eosin (H&E)}-stained sections of the small intestine following LPS injection was profuse epithelial sloughing (Figure 2a). The sloughed enterocytes were mostly single cells with very few fragments of the epithelium. Although sometimes there were signs of villus tip destruction, generally the epithelial architecture appeared intact (Figure 2a).

To assess barrier function, mice were gavaged with FITC-dextran and ampicillin-resistant commensal strain of \textit{E. coli}. FITC-dextran is commonly used to study passage of high molecular weight substances across the epithelium. Commensal strains of \textit{E. coli} were used to examine bacterial translocation across the barrier. Our attempts to use \textit{E. coli} K12 for this purpose were unsuccessful, presumably due to poor survival of this strain in the gastrointestinal tract (unpublished data). The serum concentration of FITC-dextran and \textit{E. coli} translocation to lymphatic organs (mesenteric lymph nodes + spleen) were determined 16 h after LPS injection or CLP. As expected, acute endotoxemia resulted in dramatically increased serum FITC-dextran, and bacterial translocation (Figure 2b). Even more dramatic barrier dysfunction was observed in the CLP model (Figure 2c).

To evaluate the state of TJ, we performed immunostaining of intestinal thin sections with antibodies against the TJ-associated proteins ZO-1 and JAM-A. Control epithelia displayed prominent immunoreactivity of both proteins at enterocyte borders, consistent with localization to TJ. Some of the signal was intracellular (Figures 2c and d, NS and sham), which is in agreement with equilibrium between internalization and re-deposition of junctional proteins in the process of dynamic remodeling of TJ (20). In animals subjected to LPS injection, localization of ZO-1 and JAM-A to enterocyte borders was less pronounced, whereas intracellular localization was more pronounced. In many enterocytes the signal was diffusely spread over the cell (Figures 2c and d, LPS), indicating increased internalization of...
junctional proteins and derangement of TJ. Similar pathologic changes were observed in the CLP model (Figures 2c and d, CLP). Because virtually no signal was observed when primary antibodies were substituted for normal rabbit serum, immunostaining for JAM-A and ZO-1 was specific. Thus, in two different models, peritonitis was associated with sloughing of the intestinal epithelium, increased gut barrier permeability to macromolecules and bacteria, and increased internalization of TJ proteins, all indicating derangement of the gut barrier.

**Luminally applied PGE$_2$ increases barrier permeability in vivo**

Systemic inflammation is intricately associated with elevation of COX-2-derived prostanoids in multiple tissues (73). To dissect the role of inflammatory prostanoids in the gut barrier failure, it was necessary to separate the effects of prostanoids from the effects of other inflammatory factors known to participate in this process. Since prostanoids act in temporally- and spatially-restricted manner, and EP receptors tend to localize to the luminal aspect of the epithelium, gut-specific effects can be achieved by local, as opposed to systemic, application. Accordingly, we tested the ability of luminally instilled PGE$_2$ to increase FITC-dextran transfer from the lumen into the bloodstream. Prior to experiment mice were gavaged with the test solution containing FITC-dextran. Following isoflurane anesthesia, a loop of distal ileum was externalized and a segment was clamped. A solution of PGE$_2$ or equal amount of solvent was injected into the lumen of the isolated segment. Animals were kept under anesthesia for 25 min to allow solute translocation across the barrier, and serum FITC-dextran concentrations were then measured. Luminally instilled PGE$_2$ caused dramatic elevation of serum FITC-dextran (Figure 3), indicating that locally applied PGE$_2$ increases gut barrier permeability.

**Low dose of Celecoxib partially ameliorates barrier derangement during peritonitis**

Our data indicated that levels of COX-2 and its product PGE$_2$ in the intestine increase during experimental peritonitis. Furthermore, luminal application of PGE$_2$ increased intestinal barrier permeability. If upregulation of COX-2 contributes to the inflammatory gut barrier failure, inhibition of this enzyme could help preserve the barrier by reversing this effect. To determine whether inhibition of COX-2 might limit barrier dysfunction, we assessed barrier integrity in LPS-injected or CLP-operated mice treated with various doses of the specific COX-2 inhibitor Celecoxib.

Mice were treated with Celecoxib at doses of 0 – 5 mg/kg prior to LPS injection. The drug was introduced by oral gavage together with the test mixture of FITC-dextran and ampicillin-resistant E. coli. Serum levels of FITC-dextran and bacterial translocation were measured 16 h after LPS injection. Levels of FITC-dextran and bacterial translocation were significantly reduced by 0.5 mg/kg Celecoxib. However, higher doses provided no protection (1 mg/kg), or even exacerbated gut barrier failure (5 mg/kg, Figures 4a and b). The 0.25 mg/kg dose did not have significant effect on barrier function during endotoxemia (unpublished results). When *E. coli* translocation to lymphoid organs and liver was used as readout for barrier integrity, there was similar dose-dependent effect of Celecoxib: significant protection at 0.5 and 1 mg/kg; and no protection at 5 mg/kg (Figure 4c, d, and e).
At 5 mg/kg, Celecoxib caused relatively mild, yet significant barrier impairment by itself, in the absence of inflammatory stimuli (Figures 4a, b, and c).

Having established protective effect of low doses of Celecoxib on barrier function, we next sought to determine what effect this drug might have on other aspects of epithelial homeostasis. In the range of doses used, Celecoxib failed to significantly reduce epithelial sloughing during peritonitis (unpublished results). However, at 0.5 mg/kg Celecoxib reversed the increased internalization of the TJ-associated proteins JAM-A and ZO-1 following LPS injection or CLP (Figures 5 a–d), which is consistent with improved barrier function. Celecoxib somewhat reduced mucosal accumulation of IL-6, an inflammatory cytokine with a prominent role in intestinal inflammation, although the reduction was insignificant (unpublished data). Celecoxib significantly reduced mucosal levels of PGE\(_2\) during peritonitis (Figure 6a), and dramatically attenuated induction of the two hallmark inflammatory enzymes, COX-2 and inducible nitric oxide synthase (Figures 6b and c). In summary, Celecoxib, administered at lower, but not at higher doses, protected the epithelial barrier during experimental peritonitis and reduced expression of several key inflammatory factors.

**Discussion**

In this report we present evidence for the role of COX-2-derived prostanoids in gut barrier failure during peritonitis. Upon induction of experimental peritonitis by LPS injection or CLP there are multiple signs of gut barrier failure including epithelial sloughing, increased permeability to FITC-dextran, bacterial translocation, and internalization of TJ-associated proteins. At the same time, COX-2 is induced and levels of PGE\(_2\) increase in the mucosa. COX-2 induction is most prominent in the epithelium. Expression of COX-2 in the epithelial cells is consistent with our previous findings (63). The fact that epithelial cells express full complement of prostaglandin E receptors raises the possibility of autocrine response to inflammatory PGE\(_2\) in enterocytes. The causal relationship between COX-2-derived prostanoids and gut barrier failure is supported by the fact that luminally applied PGE\(_2\) increases barrier permeability in the absence of systemic inflammation. The role of COX-2 as a factor in gut barrier failure is further supported by the beneficial effect of COX-2 attenuation with the specific inhibitor Celecoxib.

Effects of Celecoxib in the inflammatory gut barrier failure are double-edged. We have found that lower doses (0.5–1 mg/kg), but not the higher dose (5 mg/kg) of this drug provide significant barrier protection in the endotoxemia model. In fact, the 5 mg/kg dose caused significant barrier derangement by itself, in the absence of an inflammatory stimulus, and it exacerbated barrier damage during endotoxemia. For comparison, the average daily dose of Celecoxib for treating rheumatoid arthritis and other inflammatory disorders in human patients is 5 mg/kg. A corresponding mouse dose should be 2–5 times higher due to faster metabolism in smaller animals (74). An optimal therapeutic dose of Celecoxib for gut barrier protection is therefore at least an order of magnitude lower than a typical clinical dose. The double-edged effect of Celecoxib on barrier function may be explained by a dual role of PGE\(_2\) in the pathogenesis of inflammatory gut barrier failure. Lower levels of PGE\(_2\) resulting from constitutive expression of COX-1 and basal expression of COX-2 might
protect the intestine by regulating ion transport, secretion, blood supply, and smooth muscle tone via the high affinity PGE2 receptors. It is also possible that low concentrations of PGE2 promote barrier integrity by regulating turnover of TJ proteins. Thus, a certain level of COX-2 activity might be required for the intestinal homeostasis and protection, whereas higher levels typically associated with exuberant inflammation might be pathogenic. Such dual role of COX-2 has been suspected (75) but never demonstrated. A lower dose of a COX-2 inhibitor, as exemplified by 0.5 and 1 mg/kg in our mouse experiments, might blunt the pathogenic inflammatory burst of COX-2 activity while preserving the protective function of this enzyme.

The LPS dose of 40 mg/kg might seem excessive. However, our assumption was that gut origin sepsis would typically occur under conditions of severe systemic inflammation, which our intent was to mimic. Even at 40 mg/kg, LPS caused still lesser degree of inflammation than CLP. Various studies have found vastly different LD$_{50}$ for LPS in mice, from as low as 1.2 mg/kg to as high as 50 mg/kg. These differences are likely due to different potencies of LPS from different sources, and different sensitivities to LPS of different strains of mice.

Although low doses of Celecoxib protect the intestinal barrier during peritonitis, this protection is only partial. Levels of pathologic FITC-dextran transfer and bacterial translocation during peritonitis decrease significantly upon treatment with 0.5–1 mg/kg Celecoxib, but they still remain above the background. At 0.25 – 5 mg/kg, Celecoxib does not noticeably reduce enterocyte sloughing or IL-6 expression during peritonitis. These partial effects support the idea of gut barrier failure as a multi-factorial phenomenon, to which COX-2-derived prostanoids contribute alongside a plethora of other pathogenic and protective factors (76). The fact that cox-2$^{-/-}$ mice are protected against endotoxemia (77), but have exacerbated barrier dysfunction during polymicrobial sepsis (78) also indicates that COX-2 is not the only actor in the drama of inflammatory gut barrier failure. The mechanisms by which PGE$_2$ regulates the intestinal barrier remain largely unknown. In Caco-2 enterocyte monolayers, high concentrations of PGE$_2$ increase TJ permeability via EP1 and EP4 receptors, Ca$_{2+}$ release, and myosin light chain kinase (45). A similar mechanism might operate in vivo. Another possibility is that high levels of PGE$_2$ contribute to barrier failure by enhancing other inflammatory responses. Our observation of decreased induction of iNOS and COX-2 during peritonitis in mice treated with low dose Celecoxib might be consistent with this mechanism. Furthermore, reduction of COX-2 protein expression by Celecoxib may indicate that this drug interrupts a putative positive feedback regulation of the COX-2 gene by its end product, PGE$_2$ (79). Nevertheless, because luminal application of PGE$_2$ rapidly increases barrier permeability in the absence of systemic inflammation, we believe that the effect of high levels of PGE$_2$ on the barrier is direct. The putative mechanisms behind PGE$_2$-induced gut barrier failure and protective effect of low dose Celecoxib are summarized in Figure 7.

Our findings suggest that low doses of selective COX-2 inhibitors may find use as adjunct gut barrier protection therapy in critically ill patients. The same approach may be useful in the broad array of intestinal inflammatory disorders whereby gut barrier failure plays a prominent role, e.g. necrotizing enterocolitis, Crohn’s disease, and inflammatory bowel disease. Randomized clinical trials are needed to establish the validity of this approach.
Acknowledgments

Grant support: National Institutes of Health Grant R01 AI 014032 to H.R.F.

The authors have no conflicting financial interests. We thank Larry Wang for help with microscopic pathology. This study was supported by National Institutes of Health Grant R01 AI 014032 to H.R.F.

Abbreviations

CLP  cecal ligation and puncture
H&E  hematoxylin and eosin
NS   normal saline
PGE  prostaglandin E
TJ   tight junctions

References

1. Alverdy JC, Chang EB. The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away. J Leukoc Biol. 2008 Mar; 83(3):461–6. [PubMed: 18160538]
2. Deitch EA. Gut-origin sepsis: evolution of a concept. Surgeon. Dec; 10(6):350–6. [PubMed: 22534256]
3. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin. 2005 Apr; 21(2):177–96. [PubMed: 15781156]
4. Gatt M, Reddy BS, MacFie J. Review article: bacterial translocation in the critically ill--evidence and methods of prevention. Aliment Pharmacol Ther. 2007 Apr 1; 25(7):741–57. [PubMed: 17373913]
5. Petrosyan M, Guner YS, Williams M, Grishin A, Ford HR. Current concepts regarding the pathogenesis of necrotizing enterocolitis. Pediatr Surg Int. 2009 Apr; 25(4):309–18. [PubMed: 19301015]
6. Luyer MD, Jacobs JA, Vreugdenhil AC, Hadfoune M, Dejong CH, Buurman WA, et al. Enteral administration of high-fat nutrition before and directly after hemorrhagic shock reduces endotoxemia and bacterial translocation. Ann Surg. 2004 Feb; 239(2):257–64. [PubMed: 14745335]
7. Saint MS, Liberati DM, Diebel LN. Sequential changes in mucosal immunity after hemorrhagic shock. Am Surg. 2001 Aug; 67(8):797–801. [PubMed: 11510587]
8. Sheth SU, Lu Q, Twelker K, Sharpe SM, Qin X, Reino DC, et al. Intestinal mucus layer preservation in female rats attenuates gut injury after trauma-hemorrhagic shock. J Trauma. Feb; 68(2):279–88. [PubMed: 20154538]
9. Chen LW, Hwang B, Wang JS, Chen JS, Hsu CM. Hypertonic saline-enhanced postburn gut barrier failure is reversed by inducible nitric oxide synthase inhibition. Crit Care Med. 2004 Dec; 32(12): 2476–84. [PubMed: 15599154]
10. Olguin F, Araya M, Hirsch S, Brunser O, Ayala V, Rivera R, et al. Prebiotic ingestion does not improve gastrointestinal barrier function in burn patients. Burns. 2005 Jun; 31(4):482–8. [PubMed: 15896512]
11. Reys LG, Ortiz-Pomales YT, Lopez N, Cheadle G, de Oliveira PG, Eliceiri B, et al. Uncovering the neuroenteric-pulmonary axis: Vagal nerve stimulation prevents acute lung injury following hemorrhagic shock. Life Sci. Feb 22.
12. Fishman JE, Levy G, Alli V, Sheth S, Lu Q, Deitch EA. Oxidative modification of the intestinal mucus layer is a critical but unrecognized component of trauma hemorrhagic shock-induced gut
13. Lau LL, Halliday MI, Lee B, Hannon RJ, Gardiner KR, Soong CV. Intestinal manipulation during elective aortic aneurysm surgery leads to portal endotoxaemia and mucosal barrier dysfunction. Eur J Vasc Endovasc Surg. 2000 Jun; 19(6):619–24. [PubMed: 10873730]

14. Li Z, Yang X, Lu L, Yu Y, Yao Y. Gut barrier function damage following multiple firearm injuries in a porcine model. Chin Med Sci J. 2001 Dec; 16(4):209–13. [PubMed: 12903757]

15. Peregudov SI, Khanevich MD. The small intestine as the origin of bacteremia in acute diffuse peritonitis. Nutr Hosp. 1996 Nov-Dec;11(6):317–20. [PubMed: 9025333]

16. Rahman SH, Ammori BJ, Holmfield J, Larvin M, McMahon MJ. Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis. J Gastrointest Surg. 2003 Jan; 7(1): 26–35. discussion -6. [PubMed: 12559182]

17. Souza DG, Vieira AT, Soares AC, Pinho V, Nicoli JR, Vieira LQ, et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses. J Immunol. 2004 Sep 15; 173(6):4137–46. [PubMed: 15356164]

18. Deitch EA. Role of the gut lymphatic system in multiple organ failure. Curr Opin Crit Care. 2001 Apr; 7(2):92–8. [PubMed: 11373517]

19. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol. 2006 Dec; 169(6):1901–9. [PubMed: 17148655]

20. Chalmers AD, Whitley P. Continuous endocytic recycling of tight junction proteins: how and why? Essays Biochem. 53:41–54. [PubMed: 22928507]

21. Al-Sadi R, Guo S, Dokladny K, Smith MA, Ye D, Kaza A, et al. Mechanism of interleukin-1beta induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res. Oct; 32(10): 474–84. [PubMed: 22817402]

22. Al-Sadi R, Ye D, Said HM, Ma TY. Cellular and molecular mechanism of interleukin-1beta modulation of Caco-2 intestinal epithelial tight junction barrier. J Cell Mol Med. Apr; 15(4):970–82. [PubMed: 20406328]

23. Colgan SP, Resnick MB, Parkos CA, Delp-Archer C, McGuirk D, Bacarra AE, et al. IL-4 directly modulates function of a model human intestinal epithelium. J Immunol. 1994 Sep 1; 153(5):2122–9. [PubMed: 7914217]

24. Yang R, Han X, Uchiyama T, Watkins SK, Yakuchi A, Delude RL, et al. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol. 2003 Sep; 285(3):G621–9. [PubMed: 12773301]

25. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003 Dec 1; 171(11):6164–72. [PubMed: 14634132]

26. Costantini TW, Derej J, Loomis W, Putnam JG, Choi S, Baird A, et al. Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated Caco-2 intestinal monolayers. Life Sci. 2009 Jan 2; 84(1–2):18–22. [PubMed: 18992758]

27. Hindryckx P, De Vos M, Jacques P, Ferdinand L, Peeters H, Olievier K, et al. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol. Nov 15; 185(10):6306–16. [PubMed: 20943999]

28. Paiotti AP, Ribeiro DA, Silva RM, Marchi P, Oshima CT, Neto RA, et al. Effect of COX-2 inhibitor lumiracoxib and the TNF-alpha antagonist etanercept on TNBS-induced colitis in Wistar rats. J Mol Histol. Jun; 43(3):307–17. [PubMed: 22426941]

29. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypanse B, Van Assche G, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol. 2002 Aug; 97(8):2000–4. [PubMed: 12190167]

30. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, et al. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006 Oct; 131(4):1153–63. [PubMed: 17030185]
31. Yajima S, Morisaki H, Serita R, Suzuki T, Katori N, Asahara T, et al. Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit Care Med. 2009 Mar; 37(3):1024–30. [PubMed: 19237913]

32. Beaurepaire C, Smyth D, McKay DM. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res. 2009 Mar; 29(3):133–44. [PubMed: 19196071]

33. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J. 2005 Jun; 19(8):923–33. [PubMed: 15923402]

34. Luyer MD, Buurman WA, Hadfoune M, Wolfs T, van’t Veer C, Jacobs JA, et al. Exposure to bacterial DNA before hemorrhagic shock strongly aggravates systemic inflammation and gut barrier loss via an IFN-gamma-dependent route. Ann Surg. 2007 May; 245(5):795–802. [PubMed: 17457174]

35. Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell. 2005 Oct; 16(10):5040–52. [PubMed: 16055505]

36. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 2002 Sep; 123(3):790–802. [PubMed: 12198705]

37. Yang R, Miki K, Oksala N, Nakao A, Lindgren L, Killeen ME, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol. 2009 Aug; 297(2):R362–9. [PubMed: 19494177]

38. Dickinson E, Tuncer R, Nadler E, Boyle P, Alber S, Watkins S, et al. NOX, a novel nitric oxide scavenger, reduces bacterial translocation in rats after endotoxin challenge. Am J Physiol. 1999 Dec; 277(6 Pt 1):G1281–7. [PubMed: 10600826]

39. Han X, Fink MP, Yang R, Delude RL. Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock. 2004 Mar; 21(3):261–70. [PubMed: 14770040]

40. Suzuki Y, Deitch EA, Mishima S, Lu Q, Xu D. Inducible nitric oxide synthase gene knockout mice have increased resistance to gut injury and bacterial translocation after an intestinal ischemia-reperfusion injury. Crit Care Med. 2000 Nov; 28(11):3692–6. [PubMed: 11098795]

41. Upperman JS, Potoka D, Grishin A, Hackam D, Zamora R, Ford HR. Mechanisms of nitric oxide-mediated intestinal barrier failure in necrotizing enterocolitis. Semin Pediatr Surg. 2005 Aug; 14(3):159–66. [PubMed: 16084403]

42. Lejeune M, Leung P, Beck PL, Chadee K. Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol. Nov; 299(5):G1097–105. [PubMed: 20813914]

43. Martin-Venegas R, Roig-Perez S, Ferrer R, Moreno JJ. Arachidonic acid cascade and epithelial barrier function during Caco-2 cell differentiation. J Lipid Res. 2006 Jul; 47(7):1416–23. [PubMed: 16585783]

44. Rodriguez-Lagunas MJ, Ferrer R, Moreno JJ. Effect of eicosapentaenoic acid-derived prostaglandin E on intestinal epithelial barrier function. Prostaglandins Leukot Essent Fatty Acids. Feb 27.

45. Rodriguez-Lagunas MJ, Martin-Venegas R, Moreno JJ, Ferrer R. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol. Aug; 299(2):C324–34. [PubMed: 20484658]

46. Loftin CD, Tiano HF, Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002 Aug;68–69:177–85.

47. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology. 1985 Nov; 89(5):1162–88. [PubMed: 3930341]

48. Takeuchi K, Kato S, Amagase K. Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J Pharmacol Sci. 114(3):248–61. [PubMed: 21041985]

49. Hirata T, Narumiya S. Prostanoids as regulators of innate and adaptive immunity. Adv Immunol. 116:143–74. [PubMed: 23063076]
50. Perini RF, Ma L, Wallace JL. Mucosal repair and COX-2 inhibition. Curr Pharm Des. 2003; 9(27):2207–11. [PubMed: 14529401]

51. Nakayama Y, Omote K, Namiki A. Role of prostaglandin receptor EP1 in the spinal dorsal horn in carrageenan-induced inflammatory pain. Anesthesiology. 2002 Nov; 97(5):1254–62. [PubMed: 12411813]

52. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest. 2001 Feb; 107(3):325–31. [PubMed: 11160156]

53. Samet W, Hennerbichler S, Glaser S, Wintersteiger R, Juan H. Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2alpha), in some isolated smooth muscle preparations. Br J Pharmacol. 2000 Aug; 130(8):1903–10. [PubMed: 10952681]

54. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest. 2001 Feb; 107(3):325–31. [PubMed: 11160156]

55. MacDermott RP. Alterations in the mucosal immune system in ulcerative colitis and Crohn’s disease. Med Clin North Am. 1994 Nov; 78(6):1207–31. [PubMed: 7967905]

56. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. J Immunol. 2007 Jun 15; 178(12):8138–47. [PubMed: 17548652]

57. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. Feb 11; 29(6):781–8. [PubMed: 19946299]

58. Lugo B, Ford HR, Grishin A. Molecular signaling in necrotizing enterocolitis: regulation of intestinal COX-2 expression. J Pediatr Surg. 2007 Jul; 42(7):1165–71. [PubMed: 17618875]

59. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol. 2001 Nov; 431(1):91–102. [PubMed: 11716847]

60. Martin AR, Villegas I, La Casa C, Alarcon de la Lastra C. The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulfonic acid in rats. Eur J Pharmacol. 2003 Nov 28; 481(2–3):281–91. [PubMed: 14642796]

61. Moses T, Wagner L, Fleming SD. TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage. J Leukoc Biol. 2009 Oct; 86(4):971–80. [PubMed: 19564573]

62. Zamuner SR, Warrier N, Buret AG, MacNaughton WK, Wallace JL. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut. 2003 Dec; 52(12):1714–20. [PubMed: 14633948]

63. Grishin AV, Wang J, Potoka DA, Hackam DJ, Upperman JS, Boyle P, et al. Lipopolysaccharide induces cyclooxygenase-2 in intestinal epithelium via a noncanonical p38 MAPK pathway. J Immunol. 2006 Jan 1; 176(1):580–8. [PubMed: 16365453]

64. Singh VP, Patil CS, Jain NK, Kulkarni SK. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology. 2004 Oct; 72(2):77–84. [PubMed: 15331912]

65. Tsubouchi R, Hayashi S, Aoi Y, Nishio H, Terashima S, Kato S, et al. Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. Digestion. 2006; 74(2):91–100. [PubMed: 17143008]

66. Zhang L, Lu YM, Dong XY. Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin J Dig Dis. 2004; 5(3):110–4. [PubMed: 15612245]

67. Carothers AM, Davids JS, Damas BC, Bertagnolli MM. Persistent cyclooxygenase-2 inhibition downregulates NF-κB, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res. Jun 1; 70(11):4433–42. [PubMed: 20484034]

68. Paiotti AP, Marchi P, Misiputien SJ, Oshima CT, Franco M, Ribeiro DA. The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis. In Vivo. May-Jun; 26(3):381–93. [PubMed: 22523290]
69. Ishikawa TO, Oshima M, Herschman HR. Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis. Mar; 32(3):417–26. [PubMed: 21156970]

70. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest. 2000 Feb; 105(4):469–78. [PubMed: 10683376]

71. Hotz-Behofsits C, Simpson RJ, Walley M, Bjarnason IT. Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. Scand J Gastroenterol. Aug; 45(7–8):822–7. [PubMed: 20441531]

72. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moldawer LL, Efron PA. Cecal ligation and puncture. Curr Protoc Immunol. Nov. Chapter 19(Unit 19):3.

73. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004 Jul; 36(7):1187–205. [PubMed: 15109566]

74. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 Mar; 22(3):659–61. [PubMed: 17942826]

75. Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed. 2007 Aug; 78(2):96–110. [PubMed: 17933277]

76. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. Feb; 70(4):631–59. [PubMed: 22782113]

77. Ejima K, Layne MD, Carvajal IM, Kritek PA, Baron RM, Chen YH, et al. Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. FASEB J. 2003 Jul; 17(10):1325–7. [PubMed: 12738799]

78. Fredenburgh LE, Velandia MM, Ma J, Olszak T, Cernadas M, Englert JA, et al. Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. J Immunol. Nov 15; 187(10):5255–67. [PubMed: 21967897]

79. Ishikawa TO, Jain N, Herschman HR. Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo. Biochem Biophys Res Commun. 2009 Jan 16; 378(3):534–8. [PubMed: 19061862]
Figure 1. Expression of COX-2, PGE₂, and PGE₂ receptors during peritonitis. (a) COX-2 protein expression in the ileal mucosa 16 h after control treatments (normal saline, NS, and sham), LPS injection, or CLP. Pos and Neg, positive and negative controls, IEC-6 cells treated with and without LPS. β-actin reprobe is shown to demonstrate lane load. Positions of size markers and their molecular weight in kD are on the left. Bar graph shows COX-2 band densities normalized to actin signal. *, significant differences, p<0.01. Data are representative of 3 independent experiments with 1 animal in each group. (b) Levels of stable PGE₂ metabolites in ileal mucosa 16 h after indicated treatments. Data are average ±SEM of 3 animals for each data point. Significant differences **(p=0.44), # (p=0.005). (c) Localization of COX-2 (red) in the ileum 16 h after indicated treatments. Neg, negative control, intestinal section from cox-2⁻/⁻ animal stained for COX-2. (d) Localization of indicated PGE₂ receptors (red) in the ileum 16 h after i.p. injection with normal saline. Neg, negative control, a section stained with normal serum substituting primary antibody. DAPI-stained nuclei appear in blue. Bar=100 μm. All immunofluorescence images are representative of at least 3 animals in each group.
Figure 2. Peritonitis is associated with gut barrier derangement
(a) H&E-stained sections of ileum from mice 16 h after injection with NS, injection with 40 mg/kg LPS, sham operation, or CLP. Note abundant epithelial sloughing in animals injected with LPS or subjected to CLP. Data are representative of at least 9 animals in each group.
(b) Transepithelial passage of FITC-dextran and bacteria during peritonitis. Mice were gavaged with FITC-dextran and *E. coli* 35354T prior to indicated treatments. Serum concentrations of FITC-dextran (top) and counts of viable *E. coli* in combined mesenteric lymph nodes and spleens (bottom) were determined 16 h post treatment. *, Significant differences (p ≤0.01, n ≥12 in each group).
(c) Localization of JAM-A (red) in ileal epithelium 16 h after indicated treatments. Note increased re-distribution of JAM-A from borders to intracellular space of enterocytes in LPS and CLP samples. (d) Localization of ZO-1 (red) in ileal epithelium 16 h after indicated treatments. Note increased redistribution
of ZO-1 from TJ to intracellular space of enterocytes in LPS and CLP samples. DAPI-stained nuclei appear in blue. Bar=50 μm. All images are representative of at least 3 animals in each group.
Figure 3. Luminal application of PGE$_2$ increases transepithelial passage of FITC-dextran
Mice were gavaged with FITC-dextran solution 2 h prior to experiments. Following anesthesia, 200 μl of normal saline (NS) or 50 mM PGE$_2$ (PGE2) were injected into the lumen of isolated ileal loop. Serum levels of FITC-dextran were determined 20 min after treatment. Data are average ±SEM for 5 animals in each group. *, Significant difference at p=0.02.
Figure 4. Dose-dependent effects of Celecoxib on gut barrier permeability during peritonitis
Mice were gavaged with the test mixture of FITC-dextran and *E. coli* prior to experiments. Celecoxib at indicated doses (mg/kg) or vehicle were added to the test mixture. (a) Serum FITC-dextran levels 16 h after injection with NS or LPS, with or without various doses of Celecoxib, as indicated. (b) Serum FITC-dextran levels 16 h after sham operation or CLP, with or without various doses of Celecoxib, as indicated. (c) *E. coli* counts in lymphatic organs 16 h after injection with NS or LPS, with or without various doses of Celecoxib, as indicated. (d) *E. coli* counts in lymphatic organs 16 h after sham operation or CLP, with or without Celecoxib, as indicated. (e) *E. coli* counts in liver 16 h after indicated treatments, with or without 0.5 mg/kg Celecoxib, as indicated. Data are average ± SEM, n≥12 in each group. Significant differences: *, p ≤0.01 vs. LPS or CLP alone; **, p ≤0.02 vs. LPS or CLP alone; #, p ≤0.02 vs. NS or sham.
Figure 5. Effects of Celecoxib on localization of TJ-associated proteins JAM-A and ZO-1
(a) JAM-A (red) after injection with NS or LPS, with or without indicated doses (mg/kg) of Celecoxib. (b) JAM-A (red) after sham operation or CLP, with or without indicated doses of Celecoxib. (c) ZO-1 (red) after injection with NS or LPS, with or without indicated doses of Celecoxib. (d) ZO-1 (red) after sham operation or CLP, with or without indicated doses of Celecoxib. All images show sections of ileal samples taken 16 h after peritonitis-inducing treatments and are representative of at least 3 animals in each group. DAPI-stained nuclei appear in blue. Bar=100 μm.
Figure 6. Effects of Celecoxib on expression of inflammatory mediators
(a) Levels of stable PGE\textsubscript{2} metabolites in the ileal mucosa 16 h after LPS injection (left) or CLP (right) and treatment with Celecoxib at indicated doses (mg/kg). Data are average ± SEM for at least 3 animals in each data point. *, significant differences from LPS alone or CLP alone, p ≤0.05. (b) COX-2 and (c) iNOS protein levels in ileal mucosa 16 h after LPS injection or CLP, with and without 0.5 mg/kg Celecoxib. β-actin reprobes are shown to demonstrate lane load. Positions of size markers and their molecular weight in kD are on the left. Bar graphs show average band densities normalized to β-actin signal. Significance levels: *p=0.022, **p=0.044, ##p=0.047. Data are representative of 3 independent experiments.
Figure 7. A diagram of the proposed role of COX-2-derived PGE\textsubscript{2} on the epithelial barrier and effects of Celecoxib.

Low levels of COX-2-derived PGE\textsubscript{2} are required for epithelial homeostasis and gut protection, whereas high levels of PGE\textsubscript{2} promote gut barrier failure. High doses of Celecoxib are not beneficial because they obliterate the protective effect of PGE\textsubscript{2}. Low doses of Celecoxib blunt the inflammatory burst of PGE\textsubscript{2} while preserving the protective effect.